Jane Street Group, LLC Eq Rx, Inc. Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.66 - $2.31 $222,532 - $309,669	-134,056 Reduced 52.06%	123,447 $274,000
Q2 2023 Aug 14, 2023	BUY	$1.61 - $1.96 $394,561 - $480,335	245,069 Added 1970.96%	257,503 $478,000
Q1 2023 May 15, 2023	SELL	$1.8 - $2.83 $25,959 - $40,814	-14,422 Reduced 53.7%	12,434 $24,000
Q4 2022 Feb 14, 2023	SELL	$2.05 - $5.5 $196 - $528	-96 Reduced 0.36%	26,856 $66,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $5.99 $37,035 - $236,000	-39,399 Reduced 59.38%	26,952 $133,000
Q2 2022 Aug 16, 2022	SELL	$3.2 - $5.69 $354,166 - $629,752	-110,677 Reduced 62.52%	66,351 $311,000
Q1 2022 May 17, 2022	BUY	$2.8 - $7.39 $495,678 - $1.31 Million	177,028 New	177,028 $731,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.